MAP kinase-activating death domain protein (MADD)

MAP kinase-activating death domain protein (MADD) is a multi-domain adaptor and guanyl-nucleotide exchange factor (GEF) encoded by the human MADD gene (chromosome 11)[1][6]. It contains a death domain that interacts directly with the death domain of tumor necrosis factor-alpha receptor 1 (TNFR1), propagating apoptotic signals and activating mitogen-activated protein kinase (MAPK) pathways[1][2][3][6]. MADD also regulates vesicular trafficking by activating Rab GTPases, which are important for exocytosis and neuronal function[2][7]. Multiple transcript variants of MADD are produced via alternative splicing, including isoforms involved in cancer and neurological disease. MADD is overexpressed in various cancers and plays a mechanistic role in apoptosis, cell survival, neurodevelopmental syndromes, and neurodegenerative processes like Alzheimer’s disease[2][3][4][5]. No drugs currently target MADD directly, but it is considered a promising pharmacological target for conditions involving apoptosis and MAPK signaling dysfunction.

Other names

MAP kinase-activating death domain proteinMADDDENNIG20RabGEFRab3GEPKIAA0358RAB3GEPDifferentially expressed in normal and neoplastic cellsInsulinoma-glucagonoma clone 20Rab3 GDP/GTP exchange factorDEEAHNEDDISHInsuloma-Glucagonoma protein 20Rab3 GDP/GTP exchange protein

Drugs or molecules targeting MADD would likely modulate apoptosis signaling or MAP kinase pathways, potentially by inhibiting the protein–protein interactions between MADD and TNF-alpha receptor or affecting GEF function on Rab GTPases[3].